Security key
09090D509
BiomX Inc. - Common Stock, par value $0.0001 per share (PHGE)
CUSIP: 09090D509
Q1 2026 13F Holders as of 31 Mar 2026
- Security type / class
- Equity / Common Stock, par value $0.0001 per share
- Total 13F shares
- 312,966
- Total 13F value
- $1,185,334
- Share change
- +10,850
- SEC-reported price per share
- $3.75
- Number of holders
- 13
- Value change
- +$76,259
- Number of buys
- 6
- Number of sells
- 3
- Shares outstanding
- 11,348,298
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q1 2026
Institutions
13
Top holders
10
PHGE full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q2 2026
Previous quarter: Q4 2025
BiomX Inc. SEC filings
BiomX Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 09090D509
Recent filing periods:
Ownership snapshot
Top reported holders of PHGE - BiomX Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Reuven Yeganeh
Disclosed value leader
OrbiMed Israel BioFund GP...
Comparable rows
15/15
Latest evidence
31 Mar 2026
13D/G
3/4/5
13F
Lead comparable stake: 20%
13D/G row: Reuven Yeganeh
Showing 1-6 of 15 holder rows.
Quick read
Reuven Yeganeh leads the comparable SEC ownership view at 20%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Reuven Yeganeh's linked filing trail.
Comparable ownership
Top 5
Reuven Yeganeh
20%
Cystic Fibrosis Foundation
10%
Nantahala Capital Management, LLC
10%
Centaurus Investments Ltd
5.2%
Alyeska Investment Group, L.P.
2.5%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Reuven Yeganeh |
13D/G
|
20%
|
$99,170
381,422 shares
|
$0 | 26 Dec 2025 |
| Cystic Fibrosis Foundation |
3/4/5
13D/G
10%+ Owner
|
10%
from 13D/G
|
$1,663,688
11,131,426 shares
mixed-class rows
|
— | 26 Feb 2025 |
| Nantahala Capital Management, LLC |
13D/G
13F
Company
|
10%
|
$355,700
156,696 shares
|
$0 | 31 Dec 2025 |
| Centaurus Investments Ltd |
13D/G
Rodney Hodges
|
5.2%
|
—
82,618 shares
|
$0 | 31 Mar 2026 |
| Alyeska Investment Group, L.P. |
13D/G
|
2.5%
|
$9,926
38,176 shares
|
-$592,254 | 31 Dec 2025 |
| OrbiMed Israel BioFund GP Limited Partnership |
3/4/5
13D/G
10%+ Owner · ORBIMED ISRAEL GP LTD.
|
1%
from 13D/G
|
$5,250,517
13,777,980 shares
mixed-class rows
|
— | 15 May 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q1 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
13
Shares
312,966
Rows available
13
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q1 2026 vs Q4 2025 Across Filers
Q4 2025 holders
10
Q1 2026 holders
13
Holder diff
3
| Investor | Q4 2025 Shares | Q1 2026 Shares | Share Diff | Share Chg % | Q4 2025 value | Q1 2026 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend